Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q1 2022 Earnings Presentation
22 slides from Bactiguard Holding Ab's earnings presentation, Apr 27, 2022
Slide 1: Investor presentation Q1 2022
Investor presentation Q1 2022 27 April, 2022 Anders Göransson, CEO Gabriella Björknert Caracciolo, CFO
Slide 2: Vision: Keeping people safe from infections
Vision: Keeping people safe from infections 2
Slide 3: Bactiguard – first quarter 2022
Bactiguard – first quarter 2022 Key Financials, Q1 2022 (Q1 2021) Sales EBITDA Net Profit Operating cash flow MSEK 55.2 (41.8) • License 36.4 (26.4) MSEK -4.0 (1.9) MSEK -16.5 (-10.5) MSEK -11.9 (-0.9) • BIP sales 15.4 (13.0) Increase of revenue mainly through higher license income. Negative EBITDA,
Slide 4: Business Highlights – License revenue
Business Highlights – License revenue Q1 2022 (Q1 2021) MSEK 32,2 (25,4) MSEK 4,2 (1,0) + 27% + 320% • The underlying business is stable on an annual • Consist of fees for contract manufacturing, basis development work and signing of new agreement • Volumes may vary between quarters and first smalle
Slide 5: Business Highlights – Bactiguard product portfolio
Business Highlights – Bactiguard product portfolio Strong growth in focus areas: BIP Foleys, CVC and Wound Care, Q1 2022 (Q1 2021) BACTIGUARD BIP PORTFOLIO • Strong growth in focus products in Q1 ‘22 over Q1 ’21 • BIP Foley, almost double, driven by markets with investment in own salesforce e.g., No
Slide 6: Right timing to fuel growth
Right timing to fuel growth 1 2 3 Strong clinical evidence Capital for growth Commercial capabilities • >200 million catheters used with no • > 220 mSEK raised during the fall of • Strengthened commercial capabilities reported adverse event 2021 to fund a fact based, focused growth for continued exp
Slide 7: Agenda
Agenda Expanded partnership with Development agreement Q1 2022 Review and results Zimmer Biomet with Dentsply Sirona 7
Slide 8: Two recent license expansions
Two recent license expansions Therapeutic area Market size billion USD License partners Orthopedics 40 Nephrology 7 Urology 3 Dental 9 Critical care / CVC 11 Wound management 10 8 Source: GlobalData Please note, numbers being further assessed
Slide 9: Zimmer Biomet – Bactiguard history
Orthopedics Zimmer Biomet – Bactiguard history After years of close collaboration Zimmer Biomet have chosen to expand the partnership 2022 Feb 2021 June Global partnership extended to include EMEA launch of hips, knees and other 2021 Jan ZNN Bactiguard extremities ZNN Bactiguard CE mark 2019 Sept Zi
Slide 10: Zimmer Biomet - expanding partnership beyond trauma
Orthopedics Zimmer Biomet - expanding partnership beyond trauma Covering multiple product segments • License and development fees of USD 1.5 million, payable in 2022 • USD 7.5 million in milestone payments, contingent on U.S. regulatory clearance for different product categories • Royalties on net s
Slide 11: Zimmer Biomet Trauma collaboration progressing
Zimmer Biomet Trauma collaboration progressing ZNN Bactiguard EMEA launch continues Trauma implants • Zimmer® Natural Nail® (ZNN) Bactiguard- implants launched across Europe • Sales picking up, first royalty paid in Q1 • Efforts ongoing to register in other regions • First patient included in Tibia
Slide 12: Agenda
Agenda Expanded partnership with Development agreement Q1 2022 Review and results Zimmer Biomet with Dentsply Sirona 12
Slide 13: Global partnership with Dentsply Sirona
Dental Global partnership with Dentsply Sirona Bactiguard enters development agreement in the dental field • Development phase ─ USD 0.9 million in development and milestone fees (approx. 1 year) • Optional License agreement ─ USD 1.1 million in milestone payments, contingent on regulatory approvals
Slide 14: Dentsply Sirona - a major global player in the dental field
Dental Dentsply Sirona - a major global player in the dental field Example: Dental implants market Global market share 2021 16% Other 41% 16% 13% 4% 9% Source: Dentsply Sirona Homepage, Global Data 2021 14
Slide 15: Agenda
Agenda Expanded partnership with Development agreement Q1 2022 Review and results Zimmer Biomet with Dentsply Sirona 15
Slide 16: Rolling 12-month revenue and EBITDA aligned with strategy
Rolling 12-month revenue and EBITDA aligned with strategy • Positive development of RTM revenues due to strengthened core business aligned with our priorities • BD license revenue was higher in Q1 2022 compared to Q4 2021 but stable on a yearly basis • BIP revenues sustainable growth mainly driven b
Slide 17: Financial overview
Financial overview Highest quarterly revenue since Covid-19 pandemic outbreak 2022 2021 Q1 2022 vs Q1 2021 Full • Revenue MSEK 55.2 (41.8) an MSEK Q1 RTM Q1 increase of 32%, currency adjusted year 23% Revenues 55,2 192,5 41,8 179,0 EBITDA -4,0 -13,1 1,9 -7,2 • EBITDA of MSEK -4.0 (1.9) EBITDA margin
Slide 18: Cash flow and liquidity
Cash flow and liquidity New share issue* in Sept 2021 enables the growth strategy • Q1 2022 negative operating cash flow of MSEK -11.9 (-0.9) due to investments in growth strategy • Overdraft facility unutilized MSEK 0.0 (-14.4) compared to March 31, 2021 • Available liquidity incl. overdraft facili
Slide 19: Global outlook
Global outlook COVID-19 situation and war in Ukraine • 508 million confirmed cases of Covid-19 • 6,2 million deaths • 11 billion vaccine doses have been administered 2020 2021 2022 • The lowest number of deaths in COVID-19 in two • Bactiguard does not operate and has no suppliers years in Russia or
Slide 20: Bactiguard infection prevention – Safe and Effective
Bactiguard infection prevention – Safe and Effective Ten reasons to invest in Bactiguard Long-term owners and Contribution to the UN’s Global dedicated management 10 1 Sustainable Development Goal. Bactiguard technology Profitable growth 9 2 - effective and safe Financial Target 2026: • Revenue >1 b
Slide 21: Questions & Answers
Questions & Answers Anders Göransson Gabriella Björknert Caracciolo CEO CFO +46 8 440 58 80 +46 8 440 58 80 anders.goransson@bactiguard.com gabriella.caracciolo@bactiguard.com 21
Slide 22: Bactiguard on the outside – safe on the inside
Bactiguard on the outside – safe on the inside